Table 3 The association of GGH, FAAH, PIR and TAF5L to the clinicopathological characteristics in addition to clinical outcomes
Characteristics | FAAH | PIR | TAF5L | GGH | ||||
|---|---|---|---|---|---|---|---|---|
Negative | Positive | Negative | Positive | Negative | Positive | Negative | Positive | |
8 (100) | 64 (100) | 11 (100) | 61 (100) | 40 (100) | 32 (100) | 18 (100) | 56 (100) | |
Survival ≥8 yrs | 4 (12) | 29 (88) | 4 (12) | 29 (88) | 18 (55) | 15 (45) | 11 (36) | 22 (64) |
Survival <8 yrs | 4 (10) | 35 (90) | 7 (18) | 32 (82) | 22 (57) | 17 (43) | 5 (16) | 34 (84) |
P = 0.55 | P = 0.53 | P = 1 | P = 0.037 | |||||
Recurrence | ||||||||
No | 3 (12) | 22 (88) | 2 (8) | 23 (92) | 16 (64) | 9 (36) | 9 (36) | 16 (64) |
Yes | 0 (0) | 18 (100) | 2 (11) | 16 (89) | 7 (39) | 11 (61) | 0 (0) | 18 (100) |
P = 0.29 | P = 0.87 | P = 0.12 | P = 0.009 | |||||
Age | ||||||||
27-59 | 2 (9) | 20 (91) | 3 (14) | 19.(86) | 12 (55) | 10 (45) | 6 (27) | 16 (73) |
≥60 | 16 (73) | 44 (88) | 8 (16) | 42 (84) | 28 (56) | 22 (44) | 12 (24) | 38 (76) |
P = 0.54 | P = 1 | P = 1 | P = 0.78 | |||||
BRE grade | ||||||||
I-II | 5 (14) | 31 (86) | 4 (11) | 32 (89) | 16 (44) | 20 (66) | 15 (42) | 21 (58) |
III | 3 (8) | 33 (92) | 7 (19) | 29 ( 81) | 24 (67) | 12 (33) | 3 (8) | 33 (92) |
P = 0.71 | P = 0.51 | P = 0.06 | P <0.001 | |||||
Axillary lymph node status | ||||||||
Negative | 2 (8) | 22 (92) | 7 (29) | 17 (71) | 14 (58) | 10 (42) | 5 (21) | 19 (79) |
Positive | 6 (13) | 42 (87) | 4 (8) | 44 (92) | 26 (54) | 22 (46) | 13 (27) | 35 (73) |
P = 0.71 | P = 0.034 | P = 0.81 | P = 0.88 | |||||
No. of axillary lymph nodes | ||||||||
1-3 | 0 (0) | 23 (100) | 1 (4) | 22 (96) | 13 (43) | 17 (57) | 6 (26) | 17 (74) |
≥4 | 6 (24) | 19 (76) | 3 (12) | 22 (88) | 10 (56) | 8 (44) | 7 (28) | 18 (72) |
P = 0.023 | P = 0.6 | P = 0.56 | P = 0.63 | |||||
ER/PR status | ||||||||
Negative | 5 (15) | 29 (85) | 4 (12) | 30 (88) | 19 (56) | 15 (44) | 10 (41) | 27 (59) |
Positive | 3 (8) | 35 (92) | 7 (18) | 31.(82) | 21 (55) | 17 (45) | 4 (10) | 34 (90) |
P = 0.46 | P = 0.52 | P = 0.26 | P = 0.01 | |||||
HER2/ neu status | ||||||||
Negative | 5 (14) | 32 (86) | 7 (19) | 30 (81) | 20 (54) | 17 (46) | 10 (71) | 4 (29) |
Positive | 1 (5) | 21 (95) | 2 (9) | 20 (91) | 13 (59) | 9 (41) | 27 (60) | 18 (40) |
P = 0.4 | P = 0.46 | P = 0.79 | P = 0.53 | |||||
FAAH | ||||||||
Negative | 2 (18) | 9 (82) | 4 (50) | 4 (50) | 5 (28) | 13 (72) | ||
Positive | 6 (10) | 55 (90) | 36 (56) | 28 (44) | 3 (6) | 51 (94) | ||
- | P = 0.6 | P = 1 | P = 0.02 | |||||
PIR | ||||||||
Negative | 2 (25) | 6 (75) | 7 (64) | 4 (36) | 2 (11) | 16 (89) | ||
Positive | 9 (14) | 55 (86) | 33 (54) | 28 (46) | 9 (17) | 45 (83) | ||
P = 0.6 | - | P = 0.74 | P = 0.72 | |||||
TAF5L | ||||||||
Negative | 4 (10) | 36 (90) | 3 (27) | 8 (73) | 5 (28) | 13 (72) | ||
Positive | 4 (13) | 28 (87) | 13 (21) | 48 (79) | 11 (20) | 43 (80) | ||
P = 1 | P = 0.7 | - | P = 0.53 | |||||
GGH | ||||||||
Negative | 5 (63) | 3 (37) | 2 (18) | 9 (82) | 8 (44) | 10 (66) | ||
Positive | 13 (20) | 51 (80) | 16 (26) | 45 (74) | 32 (59) | 22 (41) | ||
P = 0.02 | P = 0.72 | P = 0.53 | - | |||||